危重症患者亚胺培南群体药代动力学:参数与非参数模型均提示CKD-EPI估算肾小球滤过率为重要协变量
两法均以二室模型最佳,且CKD-EPI eGFR(未按体表面积校正)为消除速率常数协变量;参数估计相近,但非参数模型估测的个体间变异更高。
要点
- 危重症患者亚胺培南popPK呈二室模型,CKD-EPI eGFR为消除速率常数协变量。
- 参数与非参数模型参数估计相近,但非参数模型个体间变异估测更高。
- 个体间变异差异可能影响给药模拟中的暴露估计,需进一步模拟研究。
核心结论
- 参数与非参数模型均能较好描述危重症患者亚胺培南popPK,参数估计可比且纳入协变量相同。
- 非参数模型估测的个体间变异更高,可能影响给药模拟中的暴露估计。
研究设计与样本
- 采用参数法(NONMEM 7.2)与非参数法(Pmetrics 1.5.2)分别构建群体药代动力学模型。
主要发现
- 两法均以二室模型最佳,CKD-EPI eGFR(未按体表面积校正)为消除速率常数(Ke)协变量。
- 参数模型Ke为0.637 h-1(BSV 19.0% CV),中央分布容积Vc为29.6 L(无BSV)。
- 非参数模型Ke为0.681 h-1(34.0% CV),Vc为31.1 L(42.6% CV)。
关键数值与推荐
- 入组时CKD-EPI eGFR中位数为116 mL/min/1.73 m2(四分位距104-124)。
- 常用给药方案为500 mg/500 mg每日四次。
临床怎么用
- 危重症患者使用亚胺培南时,CKD-EPI eGFR可作为popPK模型中的重要协变量用于个体化给药。
- 参数与非参数模型个体间变异估测不同,基于模型进行剂量模拟时需注意暴露估计的差异。
局限性
- 个体间变异估测差异对给药模拟的影响尚需进一步模拟研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Population pharmacokinetic (popPK) models for antibiotics are used to improve dosing strategies and individualize dosing by therapeutic drug monitoring. Little is known about the differences in results of parametric versus nonparametric popPK models and their potential consequences in clinical practice. We developed both parametric and nonparametric models of imipenem using data from critically ill patients and compared their results. METHODS: Twenty-six critically ill patients treated with intravenous imipenem/cilastatin were included in this study. Median estimated glomerular filtration rate (eGFR) measured by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation was 116 mL/min/1.73 m2 (interquartile range 104-124) at inclusion. The usual dosing regimen was 500 mg/500 mg four times daily. On average, five imipenem levels per patient (138 levels in total) were drawn as peak, intermediate, and trough levels. Imipenem concentration-time profiles were analyzed using parametric (NONMEM 7.2) and nonparametric (Pmetrics 1.5.2) popPK software. RESULTS: For both methods, data were best described by a model with two distribution compartments and the CKD-EPI eGFR equation unadjusted for body surface area as a covariate on the elimination rate constant (Ke). The parametric population parameter estimates were Ke 0.637 h-1 (between-subject variability [BSV]: 19.0% coefficient of variation [CV]) and central distribution volume (Vc) 29.6 L (without BSV). The nonparametric values were Ke 0.681 h-1 (34.0% CV) and Vc 31.1 L (42.6% CV). CONCLUSIONS: Both models described imipenem popPK well; the parameter estimates were comparable and the included covariate was identical. However, estimated BSV was higher in the nonparametric model. This may have consequences for estimated exposure during dosing simulations and should be further investigated in simulation studies.
引用
- de Velde F, de Winter BCM, Neely MN, et al. Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate. Clin Pharmacokinet. 2020. PMID: 31956969. doi:10.1007/s40262-020-00859-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。